Hélène M. P.
- Country
- France
- Department
- 76000
Research Overview
- Non‑inferiority of Azithromycin Withdrawal vs Continuation in Stable Non‑Cystic Fibrosis Bronchiectasis after ≥1 Year of Therapy: Multicenter Randomized Controlled Trial
- A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)
- Evaluation of Amikacin Liposome Inhalation Suspension in Combination Therapy for Mycobacterium xenopi Pulmonary Infection: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 53 of 149 partner sites.
Specializations
Thoracic oncology
Clinical research activity is centered on non-small cell lung cancer, small-cell lung cancer, and other advanced thoracic malignancies, with interest in perioperative, locally advanced, and metastatic disease settings. The portfolio also includes pulmonary carcinoid and broader thoracic oncology care.
- Non-small cell lung cancer
- Small-cell lung cancer
- Metastatic lung cancer
- Esophageal and gastroesophageal junction cancer
- Malignant pleural disease
The therapeutic focus includes immunotherapy, targeted therapy, and treatment strategies for resectable and unresectable thoracic cancers.
Pulmonary medicine and respiratory failure
Research extends across chronic and progressive lung disorders, including idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial lung disease, and chronic pulmonary aspergillosis. The respiratory portfolio also covers chronic obstructive pulmonary disease, severe asthma, and pulmonary hypertension.
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Pulmonary arterial hypertension
- Chronic pulmonary aspergillosis
- Severe asthma
Additional involvement includes respiratory intensive care, acute chest syndrome, and severe infectious complications affecting the lungs.
Autoimmune and inflammatory disease
There is strong involvement in rheumatology and systemic autoimmune disease, with studies in ANCA-associated vasculitis, rheumatoid arthritis, systemic sclerosis, psoriatic arthritis, and sarcoidosis. Skin and mucosal inflammatory disorders are also represented.
- ANCA-associated vasculitis
- Rheumatoid arthritis
- Systemic sclerosis
- Psoriatic arthritis
- Mucous membrane pemphigoid
Therapeutic interest includes biologic therapy, immunomodulation, and management of refractory inflammatory disease.
Cardiovascular and thromboembolic disease
The investigator is involved in studies of atrial fibrillation, heart failure, atherosclerotic cardiovascular disease, stroke prevention, and venous thromboembolism. The cardiovascular portfolio also includes pulmonary embolism, cardiogenic shock, and post-procedural antithrombotic care.
- Atrial fibrillation
- Heart failure
- Stroke prevention
- Venous thromboembolism
- Pulmonary embolism
Key therapeutic domains include anticoagulation, cardiovascular risk reduction, and treatment of thrombotic complications in high-risk patients.
Renal, gastrointestinal, and infectious disorders
Research activity also covers chronic kidney disease, kidney transplantation, inflammatory bowel disease, hepatobiliary disease, and selected infectious diseases. This includes Crohn’s disease, ulcerative colitis, hepatitis B, and alcohol-related liver disease.
- Chronic kidney disease
- Kidney transplantation
- Crohn’s disease
- Ulcerative colitis
- Hepatitis B
Therapeutic interests include transplant immunology, renal protection, microbiota-based therapy, and treatment of complex infectious complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.